MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, AustraliaGlobeNewsWire • 12/04/19
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in CanadaGlobeNewsWire • 10/28/19
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in JapanGlobeNewsWire • 10/23/19
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in JapanGlobeNewsWire • 10/07/19
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in ChinaGlobeNewsWire • 09/30/19
MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New YorkGlobeNewsWire • 09/11/19
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New YorkGlobeNewsWire • 08/29/19